Table 1.

Some direct-acting antivirals in development in 2009.

Protease inhibitors	Polymerase-nucleoside / nonnucleoside inhibitors
• Telaprevir (Vertex) Boceprevir (Schering Plough/Merck)	• PF00868554 (Pfizer)
• TMC435350 (Tibotec)	• Idenix 184/-IDX136/316
• ITMN-191/R7227 (Roche)	• ANA598 (Anadys)
• MK7009 (Merck)	• BI 207127 NNPI (BI)
• B1201355 (BI)	• MK-3281 NNPI (Merck)
• SCH 900518 (Schering)	• ABT-072/333 NNPI (Abbott)
• BMS790052 (BMS NS5A)	• GS-9190 NNPI (Gilead)
Other novel agents
• IV Silibin – silimarin (milk thistle)
• Debio025, NIM811, SCY635 (cyclophilin inhibitors)
• Nitazoxanide (unknown mode of action)
• Taribavirin (ribavirin analogue)